Invited Talks
Invited Guest Speaker, BC COVID Research Symposium: “ASSESS-DBS Study: Mitigating The Impact Of COVID-19 On Marginalized People Through Use Of Dried Blood Spots For SARS-CoV-2 Antibody Testing” September 1, 2020
Invited Keynote Speaker, BC Centre for Disease Control Grand Rounds: “Mitigating the impact of COVID-19 on marginalized people: the ‘Accelerating SARS-CoV-2 SEroprevalence SurveyS Through Dried Blood Spots’ (ASSESS-DBS) Study” July 21, 2020
Invited Guest Speaker, Pacific AIDS Network (PAN) Presents Webinar: “Research update from the BC-HTC and Community implications". April 19, 2020.
Invited Keynote Speaker, British Columbia First Nations Health Authority Educators Forum: “Hepatitis C Infection in BC; Opportunities and Challenges Along the Path to Elimination”. March 3, 2020.
Invited Keynote Speaker, Correctional Services Canada Fraser Valley Institute for Women World Anti-bullying day event: “Staying free from hepatitis C: we’re worth it!”. February 24, 2020.
Invited Guest Speaker, Canadian Research Initiative in Substance Misuse (CRISM) Peer Team Update: “Access to Opioid Agonist Treatment in BC Provincial Corrections & Canadian Federal Corrections”. February 4, 2020
Invited Guest Speaker/Moderator, Vancouver Island Provincial Corrections Hepatitis Treatment Workshop: “Assessment and Treatment: From Corrections to Community” December 16, 2019
Invited Key Note Speaker, Vancouver Lower Mainland Hepatitis Nurse’s Journal Club: “Hepatitis C infection in BC; Opportunities and Challenges Along the Path to Elimination” December 11th, 2019
Invited Guest Speaker, British Columbia STI & HIV Public Health Nurses Monthly Meeting :“Towards hepatitis C elimination; A Quality Improvement approach” October 16, 2019.
Invited Guest Speaker, British Columbia STBBI Working Group: “Towards hepatitis C elimination; A Quality Improvement approach” June 17, 2019.
Invited Key Note Speaker: HCV in Correctional Settings Educational Event; “Opportunities & challenges for hepatitis C treatment roll-out in correctional settings”. April 2, 2019.
Guest Presenter, CATIE’s Hep C Basics blended learning course: “One size does not fit all’
hep C elimination in British Columbia”. February 21, 2019.
Invited Key Note Speaker, The Carnegie Community Centre 25th Annual World AIDS Day Seminar: ”Viral Hepatitis in British Columbia; One size does not fit all”. November 29, 2018.
Invited Key Note Speaker, BC Centre for Disease Control Grand Rounds: “Hepatitis C virus micro-elimination among prison populations: demonstration of feasibility and models of care from Australia”. October 2, 2018.
Invited Keynote Speaker, BC Centre for Disease Control Grand Rounds: “Mitigating the impact of COVID-19 on marginalized people: the ‘Accelerating SARS-CoV-2 SEroprevalence SurveyS Through Dried Blood Spots’ (ASSESS-DBS) Study” July 21, 2020
Invited Guest Speaker, Pacific AIDS Network (PAN) Presents Webinar: “Research update from the BC-HTC and Community implications". April 19, 2020.
Invited Keynote Speaker, British Columbia First Nations Health Authority Educators Forum: “Hepatitis C Infection in BC; Opportunities and Challenges Along the Path to Elimination”. March 3, 2020.
Invited Keynote Speaker, Correctional Services Canada Fraser Valley Institute for Women World Anti-bullying day event: “Staying free from hepatitis C: we’re worth it!”. February 24, 2020.
Invited Guest Speaker, Canadian Research Initiative in Substance Misuse (CRISM) Peer Team Update: “Access to Opioid Agonist Treatment in BC Provincial Corrections & Canadian Federal Corrections”. February 4, 2020
Invited Guest Speaker/Moderator, Vancouver Island Provincial Corrections Hepatitis Treatment Workshop: “Assessment and Treatment: From Corrections to Community” December 16, 2019
Invited Key Note Speaker, Vancouver Lower Mainland Hepatitis Nurse’s Journal Club: “Hepatitis C infection in BC; Opportunities and Challenges Along the Path to Elimination” December 11th, 2019
Invited Guest Speaker, British Columbia STI & HIV Public Health Nurses Monthly Meeting :“Towards hepatitis C elimination; A Quality Improvement approach” October 16, 2019.
Invited Guest Speaker, British Columbia STBBI Working Group: “Towards hepatitis C elimination; A Quality Improvement approach” June 17, 2019.
Invited Key Note Speaker: HCV in Correctional Settings Educational Event; “Opportunities & challenges for hepatitis C treatment roll-out in correctional settings”. April 2, 2019.
Guest Presenter, CATIE’s Hep C Basics blended learning course: “One size does not fit all’
hep C elimination in British Columbia”. February 21, 2019.
Invited Key Note Speaker, The Carnegie Community Centre 25th Annual World AIDS Day Seminar: ”Viral Hepatitis in British Columbia; One size does not fit all”. November 29, 2018.
Invited Key Note Speaker, BC Centre for Disease Control Grand Rounds: “Hepatitis C virus micro-elimination among prison populations: demonstration of feasibility and models of care from Australia”. October 2, 2018.
Accepted Conference Presentations
Bartlett SR, Buller-Taylor T, Teal T, Hughes S, Marion T, McMillan B, Buxton J, Sharifi N, Fong M, Beaumont A, Pick N, Erickson M, Jennings L, Luster D, Laird D, Martin RE, Moher M, Krusi A, Young S, Janjua N. “Pathways to hepatitis C care in BC Provincial Corrections: partnering with people in prison to co-create policies and guidelines” [Oral abstract presented at Canadian Liver Meeting, Virtual, Canada, May 2-5 2021].
Bartlett SR, Wong S, Yu A, Pearce M, Binka M, Samji H, Jeong D, Velasquez H, Adu P, Darvishian M, Alvarez M, Cook V, Wong J, Buxton J, Krajden M, Janjua NZ. Continued inequities in the hepatitis C cascade of care experienced by people who inject drugs in British Columbia in 2019: A population-level linked data study [Poster abstract presented at American Association for the Study of Liver Disease The Liver Meeting, Virtual, United States, November 1st, 2020 DOI: 10.1002/hep.30941]
Bartlett SR, Yu A, Pearce M, Binka M, Young S, Sharifi N, MacFarlane A,Singleton R, Fong M, Sexsmith M, Wong J, Jessem A, Alvarez M, Buxton J, Krajden M, Janjua NZ.. “Increasing hepatitis C screening & new diagnoses in 10 British Columbia Provincial Correctional Centres from 2010-2019” [Oral abstract presented at Canadian Liver Meeting, Montreal, Canada, March1st, 2020].
Bartlett SR, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Krajden M, Janjua NZ. RECENT OPIOID AGONIST THERAPY AND HEPATITIS C VIRUS TREATMENT UPTAKE AMONG PEOPLE WHO INJECT DRUGS WITH CHRONIC HEPATITIS C INFECTION IN A POPULATION BASED DATA LINKAGE STUDY [Oral Abstract]. 8th International Symposium on Hepatitis Care In Substance Users, Montreal, Canada, September 11-13th, 2019.
Bartlett SR, Pearce M, Luster D, Schmitz D, Reitz C, Mazoff CD. INCONSISTENCIES IN METHODOLOGY, REPORTING, AND SUBJECTIVE DESCRIPTION OF HEPATITIS C VIRUS REINFECTION RATES AMONG PEOPLE WHO INJECT DRUGS: POTENTIAL CONTRIBUTION TO STIGMA AND DISCRIMINATION? [Poster Abstract 007]. 8th International Symposium on Hepatitis Care In Substance Users, Montreal, Canada, September 11-13th, 2019.
Bartlett SR, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Krajden M, Janjua NZ. Hepatitis C virus treatment uptake differs according to recency of Opioid Agonist Therapy among people who inject drugs with chronic hepatitis C infection [Poster Abstract 11]. Australasian Viral Hepatitis Elimination Conference, Sydney, Australia, August 12-13, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study [Poster Abstract]. Canadian Liver Meeting, Montreal, Canada, May 24-26, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study [Oral Poster Abstract ID THU-118]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Darvishian M, Bartlett SR, Wong S, Yu A, Alvarez M, Butt ZA, , Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Cancer risk among people with HIV, HBV, and/or HCV infections [Poster Abstract]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Janjua NZ, Wong S, Rossi C, Darvishian M, Yu A, Butt ZA, Yoshida EM, Ramji A, Feld J, Binka M, Bartlett S, Pearce M, Alvarez M, Samji H, Tyndall M, Krajden M. The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort [Poster Abstract]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Hooshyar SH, Martinello M, Bartlett SR, Finlayson R, Baker D, Bloch M, Doyle JS, Yee J, Lin L, Applegate T, Hellard M, Dore GJ, Matthews GV. Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia [Poster Abstract]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce P, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. HEPATITIS C CASCADE OF CARE AMONG PEOPLE WHO INJECT DRUGS IN BRITISH COLUMBIA IN 2017 [Poster Abstract ID 1782]. 2019 Conference on Retroviruses and Opportunistic Infections (CROI),Seattle, Washington March 4-7, 2019.
Hooshyar SH, Martinello M, Bartlett SR, Finlayson R, Baker D, Bloch M, Doyle JS, Yee J, Lin L, Applegate T, Hellard M, Dore GJ, Matthews GV. HCV REINFECTION RISK FOLLOWING DAA THERAPY IN PEOPLE LIVING WITH HIV IN AUSTRALIA" [Poster Abstract ID 2153]. 2019 Conference on Retroviruses and Opportunistic Infections (CROI),Seattle, Washington USA March 4-7, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce P, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Integrating health and administrative datasets to improve quality of care: The BC-HTC [Storyboard presentation ID: 43106]. British Columbia Quality Forum 2019, Vancouver, Canada February 26-28, 2019.
Bartlett SR, Martinello M, Applegate T*, Finlayson R, Baker D, Bloch M, Doyle J, Shaw D, Hajkowicz K, Read P, Hellard M, Filep E, Yee J, Martinez M, Lamoury FMJ, Lin L, Dore GJ, Matthews GV. PREVALENCE OF NS5A RESISTANCE ASSOCIATED SUBSTITUTIONS AND HCV DAA TREATMENT OUTCOMES AMONG PEOPLE LIVING WITH HIV IN AUSTRALIA [Oral Abstract 127]. 11th Australasian Viral Hepatitis Conference, Adelaide, Australia, August 13-15, 2018.
Bartlett SR, Martinello M, Applegate T*, Finlayson R, Baker D, Bloch M, Shaw D, Read P, Hellard M, Filep E , Yee J, Lin L , Martinez M, Lamoury FMJ, Dore GJ, Matthews GV. PHYLOGENETIC CLUSTERING PATTERNS AMONG PEOPLE LIVING WITH HIV AND HEPATITIS C IN AUSTRALIA [Oral Abstract 128]. 11th Australasian Viral Hepatitis Conference, Adelaide, Australia, August 13-15, 2018.
Bartlett SR, Mala K, Booth TL, Bunde-Birouste A, Stolz A. A community-initiated pilot program using sport to address non-communicable diseases, anti-social behaviour and social inequality [Oral Abstract]. 2018 PNG Update – PNG in the year of APEC, Port Moresby, Papua New Guinea, June 14-15 2018.
Martinello M, Bartlett SR, .Dore GJ, Bopage RI, Finlayson R, Baker D, Bloch M, Filep E, Skurowski J, Lin L, Applegate T, Hellard M, Matthews GV. Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia [Poster Abstract THU-404]. THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, April 11-15, 2018.
Bartlett SR, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recent hepatitis C virus infection between 2004-2015, among people with and without HIV co-infection [Oral Abstract]. 6th International Symposium on Hepatitis Care In Substance Users, New York, United States, September 6-8th, 2017.
Bartlett SR, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recent hepatitis C virus infection between 2004-2015, among people with and without HIV co-infection [Poster Abstract]. Australasian Viral Hepatitis Elimination Conference, Cairns, Australia, August 10-11, 2017.
Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Methods for sequencing of hepatitis C virus to detect direct-acting antiviral resistance: Systematic review & expert guidance [Oral Abstract]. 12th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Barossa Valley, Australia, June 7-9th, 2017.
Bartlett S, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recently acquired hepatitis C virus infection from 2004-2015 [Oral Abstract 7]. 12th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Barossa Valley, Australia, June 7-9th, 2017.
Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Bull RA, Ceccherini-Silberstein F, Douglas MW, Dore GD, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance [Poster Abstract THU-303]. THE INTERNATIONAL LIVER CONGRESS 2017, Amsterdam, the Netherlands, April 19-23, 2017.
Bartlett S, Wertheim JO, Bull R, Matthews GV, Lamoury F, Scheffler K, Hellard M, White B, Maher L, Dore GJ, Lloyd AR, Applegate T, Grebely J. Modelling the Effects Of Targeted DAA Hepatitis C Virus Treatment Strategies Using a Molecular Transmission Network Of People with Recent Infection [Oral Abstract]. 10th Australasian Viral Hepatitis Conference, Gold Coast, Australia, September 29th-October 1st, 2016.
Bartlett S, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. Molecular transmission network of recently acquired HCV in Australia [Oral Abstract 30284]. 11th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Hunter Valley, Australia, December 9-11th, 2015.
Bartlett S, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. Transmission network of people with recent hepatitis C virus infection in Australia [Poster Abstract]. 22nd International Symposium on Hepatitis C Virus and Related Viruses to be held in Strasbourg, France, October 9-13th, 2015.
Bartlett S, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. High Connectivity is Associated with HIV Co-Infection in the Transmission Network of People with Recent Hepatitis C Virus Infection in Australia [Poster Abstract]. 4th International Symposium on Hepatitis Care in Substance Users to be held in Sydney, Australia, October 27-9th 2015.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Factors associated with phylogenetic clustering and transmission dynamics of hepatitis C virus infection in Australia [Poster Abstract]. Inaugural EMBL Australia PhD Symposium, UNSW, Australia, December 3rd, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Factors associated with phylogenetic clustering of acute hepatitis C virus infection in Australia [Oral Abstract]. 9th Australasian Viral Hepatitis Conference, Alice Springs, Australia, September 17-19th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Phylogenetic Clustering of Acute Hepatitis C Virus Infection in Australia is Associated with HIV Co-Infection and Genotype 1a infection [Oral Abstract]. 21st International Symposium on Hepatitis C Virus and Related Viruses, Banff, Canada, September 7-11th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, Maher L, White B, Dore GJ, Lloyd A, Grebely J, Applegate T. Transmission dynamics of acute hepatitis C virus infection in Australia. 19th International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology, Rome, Italy, September 7-12th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Phylogenetic Clustering of Acute Hepatitis C Virus Infection in Australia is Associated with HIV Co-Infection and Genotype 1a infection [Oral Abstract]. Inaugural Postgraduate Research Symposium, The Kirby Institute, the National Drug and Alcohol Research Centre & the Centre for Social Research in Health, UNSW, Australia, August 29th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, Maher L, White B, Dore GJ, Lloyd A, Grebely J, Applegate T. Transmission dynamics of acute hepatitis C virus infection in Australia [Oral Abstract 6]. 10th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Lorne, Australia, June 4-6th, 2014.
Lamoury F, Bartlett S, Jacka B, Wong A, Matthews G, Grebely J, Dore GJ, Applegate T. Use of a novel sequence analysis method of the 5’UTR-HVR1 region for genotyping and molecular epidemiology of HCV in the ATAHC study [Poster Abstract 162]. 20th International Symposium on Hepatitis C Virus and Related Viruses, Melbourne, Australia, October 6-10, 2013.
Lamoury F, Jacka B, Bartlett S, Dore GJ, Applegate T. IFNL3 and IFNL4 genotyping using high resolution melt curve analysis for all Hepatitis C clinical samples [Poster Abstract 161]. 20th International Symposium on Hepatitis C Virus and Related Viruses, Melbourne, Australia, October 6-10, 2013.
Lamoury F, Jacka B, Bartlett S, Dore GJ, Applegate T. IL28B genotyping using high resolution melt curve analysis for all Hepatitis C clinical samples [Poster Abstract 59]. 21st St Vincent’s & Mater Health Sydney Research Symposium, Sydney, Australia, September 6, 2013.
Lamoury F, Bartlett S, Jacka B, Wong A, Matthews G, Grebely J, Dore GJ, Applegate T. Use of a novel sequence analysis method of the 5’UTR-HVR1 region for genotyping and molecular epidemiology for the ATAHC study [Oral Abstract 34]. 9th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Blue Mountains, Australia, June 5-7th, 2013.
Lamoury F, Jacka B, Bartlett S, Dore GJ, ApplegateT. IL28B genotyping using high resolution melt curve analysis for all hepatitis C clinical samples [Poster Abstract 1]. 8th Viral Hepatitis Australasian Conference, Auckland, New Zealand, September 10-12, 2012.
Lamoury F, Jacka B, Bartlett S, Dore GJ, Applegate T. A rapid and affordable research tool for IL28B genotyping: High resolution melt curve analysis [Oral Abstract 29]. 8th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Adelaide, Australia, June 4-6th, 2012.
Bartlett SR, Wong S, Yu A, Pearce M, Binka M, Samji H, Jeong D, Velasquez H, Adu P, Darvishian M, Alvarez M, Cook V, Wong J, Buxton J, Krajden M, Janjua NZ. Continued inequities in the hepatitis C cascade of care experienced by people who inject drugs in British Columbia in 2019: A population-level linked data study [Poster abstract presented at American Association for the Study of Liver Disease The Liver Meeting, Virtual, United States, November 1st, 2020 DOI: 10.1002/hep.30941]
Bartlett SR, Yu A, Pearce M, Binka M, Young S, Sharifi N, MacFarlane A,Singleton R, Fong M, Sexsmith M, Wong J, Jessem A, Alvarez M, Buxton J, Krajden M, Janjua NZ.. “Increasing hepatitis C screening & new diagnoses in 10 British Columbia Provincial Correctional Centres from 2010-2019” [Oral abstract presented at Canadian Liver Meeting, Montreal, Canada, March1st, 2020].
Bartlett SR, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Krajden M, Janjua NZ. RECENT OPIOID AGONIST THERAPY AND HEPATITIS C VIRUS TREATMENT UPTAKE AMONG PEOPLE WHO INJECT DRUGS WITH CHRONIC HEPATITIS C INFECTION IN A POPULATION BASED DATA LINKAGE STUDY [Oral Abstract]. 8th International Symposium on Hepatitis Care In Substance Users, Montreal, Canada, September 11-13th, 2019.
Bartlett SR, Pearce M, Luster D, Schmitz D, Reitz C, Mazoff CD. INCONSISTENCIES IN METHODOLOGY, REPORTING, AND SUBJECTIVE DESCRIPTION OF HEPATITIS C VIRUS REINFECTION RATES AMONG PEOPLE WHO INJECT DRUGS: POTENTIAL CONTRIBUTION TO STIGMA AND DISCRIMINATION? [Poster Abstract 007]. 8th International Symposium on Hepatitis Care In Substance Users, Montreal, Canada, September 11-13th, 2019.
Bartlett SR, Yu A, Wong S, Pearce M, Alvarez M, Samji H, Binka M, Buxton J, Butt ZA, Wong J, Gilbert M, Krajden M, Janjua NZ. Hepatitis C virus treatment uptake differs according to recency of Opioid Agonist Therapy among people who inject drugs with chronic hepatitis C infection [Poster Abstract 11]. Australasian Viral Hepatitis Elimination Conference, Sydney, Australia, August 12-13, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study [Poster Abstract]. Canadian Liver Meeting, Montreal, Canada, May 24-26, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study [Oral Poster Abstract ID THU-118]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Darvishian M, Bartlett SR, Wong S, Yu A, Alvarez M, Butt ZA, , Rossi C, Pearce M, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Cancer risk among people with HIV, HBV, and/or HCV infections [Poster Abstract]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Janjua NZ, Wong S, Rossi C, Darvishian M, Yu A, Butt ZA, Yoshida EM, Ramji A, Feld J, Binka M, Bartlett S, Pearce M, Alvarez M, Samji H, Tyndall M, Krajden M. The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort [Poster Abstract]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Hooshyar SH, Martinello M, Bartlett SR, Finlayson R, Baker D, Bloch M, Doyle JS, Yee J, Lin L, Applegate T, Hellard M, Dore GJ, Matthews GV. Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia [Poster Abstract]. EASL INTERNATIONAL LIVER CONGRESS (ILC), Vienna, Austria, April 10-14, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce P, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. HEPATITIS C CASCADE OF CARE AMONG PEOPLE WHO INJECT DRUGS IN BRITISH COLUMBIA IN 2017 [Poster Abstract ID 1782]. 2019 Conference on Retroviruses and Opportunistic Infections (CROI),Seattle, Washington March 4-7, 2019.
Hooshyar SH, Martinello M, Bartlett SR, Finlayson R, Baker D, Bloch M, Doyle JS, Yee J, Lin L, Applegate T, Hellard M, Dore GJ, Matthews GV. HCV REINFECTION RISK FOLLOWING DAA THERAPY IN PEOPLE LIVING WITH HIV IN AUSTRALIA" [Poster Abstract ID 2153]. 2019 Conference on Retroviruses and Opportunistic Infections (CROI),Seattle, Washington USA March 4-7, 2019.
Bartlett SR, Wong S, Yu A, Alvarez M, Buller-Taylor T, Butt ZA, Darvishian M, Rossi C, Pearce P, Wong J, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Integrating health and administrative datasets to improve quality of care: The BC-HTC [Storyboard presentation ID: 43106]. British Columbia Quality Forum 2019, Vancouver, Canada February 26-28, 2019.
Bartlett SR, Martinello M, Applegate T*, Finlayson R, Baker D, Bloch M, Doyle J, Shaw D, Hajkowicz K, Read P, Hellard M, Filep E, Yee J, Martinez M, Lamoury FMJ, Lin L, Dore GJ, Matthews GV. PREVALENCE OF NS5A RESISTANCE ASSOCIATED SUBSTITUTIONS AND HCV DAA TREATMENT OUTCOMES AMONG PEOPLE LIVING WITH HIV IN AUSTRALIA [Oral Abstract 127]. 11th Australasian Viral Hepatitis Conference, Adelaide, Australia, August 13-15, 2018.
Bartlett SR, Martinello M, Applegate T*, Finlayson R, Baker D, Bloch M, Shaw D, Read P, Hellard M, Filep E , Yee J, Lin L , Martinez M, Lamoury FMJ, Dore GJ, Matthews GV. PHYLOGENETIC CLUSTERING PATTERNS AMONG PEOPLE LIVING WITH HIV AND HEPATITIS C IN AUSTRALIA [Oral Abstract 128]. 11th Australasian Viral Hepatitis Conference, Adelaide, Australia, August 13-15, 2018.
Bartlett SR, Mala K, Booth TL, Bunde-Birouste A, Stolz A. A community-initiated pilot program using sport to address non-communicable diseases, anti-social behaviour and social inequality [Oral Abstract]. 2018 PNG Update – PNG in the year of APEC, Port Moresby, Papua New Guinea, June 14-15 2018.
Martinello M, Bartlett SR, .Dore GJ, Bopage RI, Finlayson R, Baker D, Bloch M, Filep E, Skurowski J, Lin L, Applegate T, Hellard M, Matthews GV. Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia [Poster Abstract THU-404]. THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, April 11-15, 2018.
Bartlett SR, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recent hepatitis C virus infection between 2004-2015, among people with and without HIV co-infection [Oral Abstract]. 6th International Symposium on Hepatitis Care In Substance Users, New York, United States, September 6-8th, 2017.
Bartlett SR, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recent hepatitis C virus infection between 2004-2015, among people with and without HIV co-infection [Poster Abstract]. Australasian Viral Hepatitis Elimination Conference, Cairns, Australia, August 10-11, 2017.
Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Methods for sequencing of hepatitis C virus to detect direct-acting antiviral resistance: Systematic review & expert guidance [Oral Abstract]. 12th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Barossa Valley, Australia, June 7-9th, 2017.
Bartlett S, Applegate T, Jacka B, Lamoury F, Bull R, Danta M, Bradshaw D, Lloyd AR, Hellard M, Dore GJ, Matthews1 GV, Grebely J. Phylogenetic clustering of recently acquired hepatitis C virus infection from 2004-2015 [Oral Abstract 7]. 12th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Barossa Valley, Australia, June 7-9th, 2017.
Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe A, Miller V, Bull RA, Ceccherini-Silberstein F, Douglas MW, Dore GD, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance [Poster Abstract THU-303]. THE INTERNATIONAL LIVER CONGRESS 2017, Amsterdam, the Netherlands, April 19-23, 2017.
Bartlett S, Wertheim JO, Bull R, Matthews GV, Lamoury F, Scheffler K, Hellard M, White B, Maher L, Dore GJ, Lloyd AR, Applegate T, Grebely J. Modelling the Effects Of Targeted DAA Hepatitis C Virus Treatment Strategies Using a Molecular Transmission Network Of People with Recent Infection [Oral Abstract]. 10th Australasian Viral Hepatitis Conference, Gold Coast, Australia, September 29th-October 1st, 2016.
Bartlett S, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. Molecular transmission network of recently acquired HCV in Australia [Oral Abstract 30284]. 11th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Hunter Valley, Australia, December 9-11th, 2015.
Bartlett S, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. Transmission network of people with recent hepatitis C virus infection in Australia [Poster Abstract]. 22nd International Symposium on Hepatitis C Virus and Related Viruses to be held in Strasbourg, France, October 9-13th, 2015.
Bartlett S, Raffa JD, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, White B, Maher L, Dore GJ, Lloyd A, Applegate T, Grebely J. High Connectivity is Associated with HIV Co-Infection in the Transmission Network of People with Recent Hepatitis C Virus Infection in Australia [Poster Abstract]. 4th International Symposium on Hepatitis Care in Substance Users to be held in Sydney, Australia, October 27-9th 2015.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Factors associated with phylogenetic clustering and transmission dynamics of hepatitis C virus infection in Australia [Poster Abstract]. Inaugural EMBL Australia PhD Symposium, UNSW, Australia, December 3rd, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Factors associated with phylogenetic clustering of acute hepatitis C virus infection in Australia [Oral Abstract]. 9th Australasian Viral Hepatitis Conference, Alice Springs, Australia, September 17-19th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Phylogenetic Clustering of Acute Hepatitis C Virus Infection in Australia is Associated with HIV Co-Infection and Genotype 1a infection [Oral Abstract]. 21st International Symposium on Hepatitis C Virus and Related Viruses, Banff, Canada, September 7-11th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, Maher L, White B, Dore GJ, Lloyd A, Grebely J, Applegate T. Transmission dynamics of acute hepatitis C virus infection in Australia. 19th International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology, Rome, Italy, September 7-12th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T. Phylogenetic Clustering of Acute Hepatitis C Virus Infection in Australia is Associated with HIV Co-Infection and Genotype 1a infection [Oral Abstract]. Inaugural Postgraduate Research Symposium, The Kirby Institute, the National Drug and Alcohol Research Centre & the Centre for Social Research in Health, UNSW, Australia, August 29th, 2014.
Bartlett S, Jacka B, Bull R, Luciani F, Matthews GV, Lamoury F, Hellard M, Teutsch S, Maher L, White B, Dore GJ, Lloyd A, Grebely J, Applegate T. Transmission dynamics of acute hepatitis C virus infection in Australia [Oral Abstract 6]. 10th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Lorne, Australia, June 4-6th, 2014.
Lamoury F, Bartlett S, Jacka B, Wong A, Matthews G, Grebely J, Dore GJ, Applegate T. Use of a novel sequence analysis method of the 5’UTR-HVR1 region for genotyping and molecular epidemiology of HCV in the ATAHC study [Poster Abstract 162]. 20th International Symposium on Hepatitis C Virus and Related Viruses, Melbourne, Australia, October 6-10, 2013.
Lamoury F, Jacka B, Bartlett S, Dore GJ, Applegate T. IFNL3 and IFNL4 genotyping using high resolution melt curve analysis for all Hepatitis C clinical samples [Poster Abstract 161]. 20th International Symposium on Hepatitis C Virus and Related Viruses, Melbourne, Australia, October 6-10, 2013.
Lamoury F, Jacka B, Bartlett S, Dore GJ, Applegate T. IL28B genotyping using high resolution melt curve analysis for all Hepatitis C clinical samples [Poster Abstract 59]. 21st St Vincent’s & Mater Health Sydney Research Symposium, Sydney, Australia, September 6, 2013.
Lamoury F, Bartlett S, Jacka B, Wong A, Matthews G, Grebely J, Dore GJ, Applegate T. Use of a novel sequence analysis method of the 5’UTR-HVR1 region for genotyping and molecular epidemiology for the ATAHC study [Oral Abstract 34]. 9th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Blue Mountains, Australia, June 5-7th, 2013.
Lamoury F, Jacka B, Bartlett S, Dore GJ, ApplegateT. IL28B genotyping using high resolution melt curve analysis for all hepatitis C clinical samples [Poster Abstract 1]. 8th Viral Hepatitis Australasian Conference, Auckland, New Zealand, September 10-12, 2012.
Lamoury F, Jacka B, Bartlett S, Dore GJ, Applegate T. A rapid and affordable research tool for IL28B genotyping: High resolution melt curve analysis [Oral Abstract 29]. 8th Annual Workshop of the Australian Centre for HIV and Hepatitis Virology Research, Adelaide, Australia, June 4-6th, 2012.
I acknowledge that I am an uninvited white settler living on the Traditional, Unceded, Ancestral, & Continually Occupied territories of the xʷməθkwəy̓əm (Musqueam), Skwxwú7mesh (Squamish), and sel̓íl̓witulh (Tsleil-waututh) Nations. I am grateful to the First Peoples of Turtle Island for their continued care and stewardship of these lands since time immemorial.
